Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03620019
Title Denosumab + Pembrolizumab in Patients With Stage IV Melanoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors UNC Lineberger Comprehensive Cancer Center
Indications

melanoma

Therapies

Denosumab + Pembrolizumab

Pembrolizumab

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.